Malic acid

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Malic acid
DrugBank Accession Number
DB12751
Background

Malic acid has been used in trials studying the treatment of Xerostomia, Depression, and Hypertension.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 134.0874
Monoisotopic: 134.021523302
Chemical Formula
C4H6O5
Synonyms
  • Malic acid

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to treatAcidosisCombination Product in combination with: Potassium hydroxide (DB11153)••••••••••••••••••••••••••• ••••••••
Used in combination to preventAcidosisCombination Product in combination with: Calcium chloride (DB01164), Sodium chloride (DB09153), Magnesium chloride (DB09407), Potassium chloride (DB00761), Sodium acetate (DB09395)••••••••••••••••••••
Used in combination to treatAcidosisCombination Product in combination with: Calcium chloride (DB01164), Potassium chloride (DB00761), Sodium chloride (DB09153), Sodium acetate (DB09395), Magnesium chloride (DB09407)••••••••••••••••••••
Used in combination to treatAcute hypokalemiaCombination Product in combination with: Potassium hydroxide (DB11153)••••••••••••••••••••••••••• ••••••••
Used in combination to treatHot water burns (scalds)Combination Product in combination with: Salicylic acid (DB00936), Benzoic acid (DB03793)••• •••••••••••••• •••••• ••••••••• ••••••••••••••• ••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Acerbine - LösungMalic acid (21.5 mg/g) + Benzoic acid (1.5 mg/g) + Salicylic acid (0.4 mg/g)SolutionTopicalPharmazeutische Fabrik Montavit Gmb H1972-08-28Not applicableAustria flag
Acerbine - SalbeMalic acid (7 mg/g) + Benzoic acid (0.5 mg/g) + Salicylic acid (0.133 mg/g)OintmentTopicalPharmazeutische Fabrik Montavit Gmb H1977-11-17Not applicableAustria flag
AKE 1100 GLUKOZLU IV SOLOSYONU, 1000 MLMalic acid (2.64 g/mL) + Acetylcysteine (0.25 g/mL) + Alanine (4.5 g/mL) + Arginine (3.6 g/mL) + D-glucose monohydrate (66 g/mL) + Glycerin (3.61 g/mL) + Glycine (4.2 g/mL) + Histidine (3.6 g/mL) + Isoleucine (1.5 g/mL) + Leucine (2.52 g/mL) + Lysine monohydrate (2.476 g/mL) + Methionine (1.6 g/mL) + Phenylalanine (1.062 g/mL) + Potassium chloride (1.865 g/mL) + Proline (4.5 g/mL) + Threonine (1.32 g/mL) + Tryptophan (0.6 g/mL) + Zinc chloride (3 mg/mL)SolutionIntravenousFRESENİUS KABİ İLAÇ SAN. VE TİC. LTD. ŞTİ.1995-03-082022-03-03Turkey flag
AKE 1100 GLUKOZLU IV SOLOSYONU, 500 MLMalic acid (2.64 g/mL) + Acetylcysteine (0.25 g/mL) + Alanine (4.5 g/mL) + Arginine (3.6 g/mL) + D-glucose monohydrate (66 g/mL) + Glycerin (3.61 g/mL) + Glycine (4.2 g/mL) + Histidine (3.6 g/mL) + Isoleucine (1.5 g/mL) + Leucine (2.52 g/mL) + Lysine monohydrate (2.476 g/mL) + Methionine (1.6 g/mL) + Phenylalanine (1.062 g/mL) + Potassium chloride (1.865 g/mL) + Proline (4.5 g/mL) + Threonine (1.32 g/mL) + Tryptophan (0.6 g/mL) + Zinc chloride (3 mg/mL)SolutionIntravenousFRESENİUS KABİ İLAÇ SAN. VE TİC. LTD. ŞTİ.1995-03-082022-03-03Turkey flag
AMINOPLASMAL-10% E INFUSIONMalic acid (1.01 g/l) + Acetylcysteine (0.5 g/l) + Alanine (13.7 g/l) + Arginine (9.2 g/l) + Asparagine (3.27 g/l) + Aspartic acid (1.3 g/l) + Glutamic acid (4.6 g/l) + Glycine (7.9 g/l) + Histidine (5.2 g/l) + Isoleucine (5.1 g/l) + Leucine (8.9 g/l) + Lysine hydrochloride (5.6 g/l) + Magnesium acetate (0.56 g/l) + Methionine (3.8 g/l) + N-acetyltyrosine (1 g/l) + Ornithine hydrochloride (2.51 g/l) + Phenylalanine (5.1 g/l) + Potassium acetate (2.45 g/l) + Proline (8.9 g/l) + Serine (2.4 g/l) + Sodium acetate (3.95 g/l) + Sodium hydroxide (0.2 g/l) + Sodium phosphate, monobasic (1.4 g/l) + Threonine (4.1 g/l) + Tryptophan (1.8 g/l) + Tyrosine (0.3 g/l) + Valine (4.8 g/l)InjectionIntravenousB. BRAUN SINGAPORE PTE LTD1991-05-13Not applicableSingapore flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as beta hydroxy acids and derivatives. These are compounds containing a carboxylic acid substituted with a hydroxyl group on the C3 carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Hydroxy acids and derivatives
Sub Class
Beta hydroxy acids and derivatives
Direct Parent
Beta hydroxy acids and derivatives
Alternative Parents
Short-chain hydroxy acids and derivatives / Fatty acids and conjugates / Dicarboxylic acids and derivatives / Alpha hydroxy acids and derivatives / Secondary alcohols / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Alcohol / Aliphatic acyclic compound / Alpha-hydroxy acid / Beta-hydroxy acid / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Dicarboxylic acid or derivatives / Fatty acid / Hydrocarbon derivative
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
C4-dicarboxylic acid, 2-hydroxydicarboxylic acid (CHEBI:6650)
Affected organisms
Not Available

Chemical Identifiers

UNII
817L1N4CKP
CAS number
6915-15-7
InChI Key
BJEPYKJPYRNKOW-UHFFFAOYSA-N
InChI
InChI=1S/C4H6O5/c5-2(4(8)9)1-3(6)7/h2,5H,1H2,(H,6,7)(H,8,9)
IUPAC Name
2-hydroxybutanedioic acid
SMILES
OC(CC(O)=O)C(O)=O

References

General References
Not Available
Human Metabolome Database
HMDB0000744
KEGG Compound
C00711
PubChem Compound
525
PubChem Substance
347828940
ChemSpider
510
BindingDB
92495
RxNav
29209
ChEBI
6650
ChEMBL
CHEMBL1455497
Wikipedia
Malic_acid

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
2, 3CompletedTreatmentDepression / Dry Mouth / Hypertension1
Not AvailableCompletedTreatmentHematological Malignancy1
Not AvailableRecruitingTreatmentDry Mouth1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionTopical
OintmentTopical
InjectionIntravenous0.5 g/l
InjectionIntravenous0.25 g/1000ml
SolutionParenteral
SolutionIntravenous
SolutionIntravenous0.3675 g/1000ml
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility218.0 mg/mLALOGPS
logP-0.87ALOGPS
logP-1.1Chemaxon
logS0.21ALOGPS
pKa (Strongest Acidic)3.2Chemaxon
pKa (Strongest Basic)-3.9Chemaxon
Physiological Charge-2Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area94.83 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity24.88 m3·mol-1Chemaxon
Polarizability10.91 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-0002-0920000000-d3afa3ad5c227740eae3
GC-MS Spectrum - GC-MS (3 TMS)GC-MSsplash10-001i-0951000000-1d993823fa816ba3cfb1
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0006-9100000000-aba7652c885a434930ef
GC-MS Spectrum - EI-BGC-MSsplash10-0002-0930000000-6a116527910d172eb561
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0002-0920000000-d3afa3ad5c227740eae3
GC-MS Spectrum - GC-MSGC-MSsplash10-001i-0951000000-1d993823fa816ba3cfb1
Mass Spectrum (Electron Ionization)MSsplash10-0076-9000000000-ad60ea592282d09e4bd8
MS/MS Spectrum - Quattro_QQQ 10V, NegativeLC-MS/MSsplash10-03e9-3900000000-6112a756a8c8c7c7cd50
MS/MS Spectrum - Quattro_QQQ 25V, NegativeLC-MS/MSsplash10-00di-9100000000-b3efe8bce2f89afcff34
MS/MS Spectrum - Quattro_QQQ 40V, NegativeLC-MS/MSsplash10-00ec-9300000000-c0aaa5301dcac30685db
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00du-9000000000-570a3e0ca92fc43d7015
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-9100000000-f551769688e538d0d4b1
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-006y-9000000000-7d7453d6030b15addf5d
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00dl-9000000000-e4342fb36b1e727f7f9a
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-006x-9000000000-407957aeecf9374f1b96
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-b6b324162f718f9434cb
13C NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
[1H,1H] 2D NMR Spectrum2D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-122.0998017
predicted
DarkChem Lite v0.1.0
[M-H]-119.42592
predicted
DeepCCS 1.0 (2019)
[M+H]+122.8973017
predicted
DarkChem Lite v0.1.0
[M+H]+122.26196
predicted
DeepCCS 1.0 (2019)
[M+Na]+122.1527017
predicted
DarkChem Lite v0.1.0
[M+Na]+130.68065
predicted
DeepCCS 1.0 (2019)

Drug created at October 21, 2016 00:01 / Updated at February 21, 2021 18:53